mRECIST Response (Hepatocellular Carcinoma)
Modified RECIST (mRECIST) response for hepatocellular carcinoma from the sums of viable, arterially enhancing tumor diameters.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Baseline sum of viable target-lesion diameters
- 60 mm
- Current sum of viable target-lesion diameters
- 38 mm
- Smallest sum since treatment started
- 60 mm
Result: Partial response (PR): a 36.7% decrease in the viable sum from the baseline of 60 mm.
The tool opens with these values already filled in. Replace them with your own.
What you enter
- Baseline sum of viable target-lesion diameters
- Current sum of viable target-lesion diameters
- Smallest sum since treatment started (nadir)
- A new lesion with the typical HCC enhancement pattern
- Unequivocal progression of non-target lesions
How this is calculated
Citation
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. Criteria as stated in World J Radiol 2025 (PMC12576714) and Cancers (Basel) 2026 (PMC13072226). Read the sources: Lencioni 2010 ↗, World J Radiol 2025 ↗, Cancers 2026 ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.